文献速递消化道肿瘤与早癌

TP53与MIR34A联合失活通过增加IL6R和PAI1水平促进小鼠结直肠癌发生与进展

Combined Inactivation of TP53 and MIR34A Promotes Colorectal Cancer Development and Progression in Mice Via Increasing Levels of IL6R and PAI1.
PubMed 文献 · Gastroenterology · 2018-08-10

在肠道上皮细胞特异性敲除Mir34a和/或Tp53的小鼠中,联合失活Mir34a与Tp53的小鼠经氧化偶氮甲烷诱导后结直肠肿瘤更大、侵袭和淋巴结转移增加,肿瘤细胞凋亡减少、增殖增加,炎症和上皮间质转化基因表达升高,表达谱类似人结直肠癌共识分子亚型4。给予抗IL6R抗体或PAI1抑制剂替普拉司汀可减少肿瘤细胞增殖、侵袭和转移。

要点

  • Mir34a与Tp53联合失活小鼠的结直肠肿瘤更大、侵袭和淋巴结转移多于对照或单基因失活小鼠。
  • 联合失活小鼠肿瘤细胞凋亡减少、增殖增加,Il6r、Stat3等炎症及上皮间质转化基因表达升高。
  • 抗IL6R抗体或替普拉司汀可减少联合失活小鼠肿瘤细胞增殖、结直肠肿瘤侵袭和转移。

核心结论

  • 在小鼠中证实Mir34a与Tp53联合失活通过增加IL6R和PAI1水平促进氧化偶氮甲烷诱导的结直肠癌发生、进展和转移。
  • 作者认为针对这些过程的抑制策略可能被开发用于减缓结直肠癌进展。

研究设计与样本

  • 研究为小鼠实验,使用肠道上皮细胞特异性Mir34a和/或Tp53失活小鼠及对照小鼠,给予氧化偶氮甲烷诱导结直肠癌发生。
  • 部分小鼠接受腹腔注射抗小鼠IL6R抗体,或饲喂含PAI1抑制剂替普拉司汀的饲料。
  • 分析了61例人原发性结肠癌中PAI1的表达和定位,并与MIR34A甲基化和TP53失活突变比较。
  • 从癌症基因组图谱门户获取628例结肠和直肠腺癌的mRNA水平、甲基化和临床特征数据。

主要发现

  • Mir34aΔIEC/Tp53ΔIEC小鼠较对照或单基因失活小鼠发生更大和更多的结直肠肿瘤,周围组织侵袭和淋巴结转移增加。
  • Mir34aΔIEC/Tp53ΔIEC小鼠肿瘤细胞较对照肿瘤细胞凋亡减少、增殖增加,炎症(包括Il6r和Stat3)及上皮间质转化相关基因表达升高。
  • Mir34aΔIEC/Tp53ΔIEC小鼠肿瘤基因表达模式与人结直肠癌共识分子亚型4(间充质、侵袭性)相似。
  • 鉴定出Pai1信使RNA为Mir34a的靶标;在显示MIR34A甲基化和TP53突变失活的原发性结肠癌样本中PAI1蛋白水平升高。
  • 给予替普拉司汀或抗IL6R抗体可减少Mir34aΔIEC/Tp53ΔIEC小鼠癌细胞增殖,并减少结直肠肿瘤侵袭和转移。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Combined inactivation of the microRNA 34a gene (MIR34A, by methylation) and the TP53 gene (by mutation or deletion) is observed in 50% of colorectal tumors that progress to distant metastases. We studied mice with intestinal disruption of Mir34a and Tp53 to investigate mechanisms of colorectal carcinogenesis and identify strategies to block these processes. METHODS: Mice with disruption of Mir34a and/or Tp53 specifically in intestinal epithelial cells (IECs) (Mir34aΔIEC mice, Tp53ΔIEC mice, and Mir34aΔIEC/Tp53ΔIEC mice) and controls (Mir34aFl/Fl/Tp53Fl/Fl) were given azoxymethane to induce colorectal carcinogenesis. Some mice were given intraperitoneal injections of an antibody against mouse interleukin 6 receptor (IL6R), or received an inhibitor of PAI1 (tiplaxtinin) in their chow. Intestinal tissues were collected and analyzed by immunohistochemistry; gene expression profiles were analyzed by RNA sequencing. We determined the expression and localization of PAI1 in 61 human primary colon cancers and compared them to MIR34A methylation and inactivating mutations in TP53. Data on mRNA levels, methylation, and clinical features of 628 colon and rectal adenocarcinomas were obtained from The Cancer Genome Atlas portal. RESULTS: Mir34aΔIEC/Tp53ΔIEC mice developed larger and more colorectal tumors, with increased invasion of surrounding tissue and metastasis to lymph nodes, than control mice or mice with disruption of either gene alone. Cells in tumors from the Mir34aΔIEC/Tp53ΔIEC mice had decreased apoptosis and increased proliferation compared to tumor cells from control mice, and expressed higher levels of genes, that regulate inflammation (including Il6r and Stat3) and epithelial-mesenchymal transition. The gene expression pattern of the tumors from Mir34aΔIEC/Tp53ΔIEC mice was similar to that of human colorectal tumor consensus molecular subtype 4 (mesenchymal, invasive). We identified the Pai1 messenger RNA as a target of Mir34a; levels of PAI1 protein were increased in primary colon cancer samples, that displayed methylation of MIR34A and mutational inactivation of TP53. Administration of tiplaxtinin or anti-IL6R antibody to Mir34aΔIEC/Tp53ΔIEC mice decreased proliferation of cancer cells, and reduced colorectal tumor invasion and metastasis. CONCLUSIONS: In mice, we demonstrated that combined inactivation of Mir34a and Tp53 promotes azoxymethane-induced colorectal carcinogenesis and tumor progression and metastasis by increasing levels of IL6R and PAI1. Strategies to inhibit these processes might be developed to slow progression of colorectal cancer.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Öner MG, Rokavec M, Kaller M, et al. Combined Inactivation of TP53 and MIR34A Promotes Colorectal Cancer Development and Progression in Mice Via Increasing Levels of IL6R and PAI1. Gastroenterology. 2018. PMID: 30099074. doi:10.1053/j.gastro.2018.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。